Beth P Hecht's Insider Trades & SAST Disclosures
Beth P Hecht's most recent trade in Xeris Biopharma Holdings Inc was a trade of 300,000 Stock Appreciation Right done . Disclosure was reported to the exchange on Jan. 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Beth P Hecht.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 300,000 | 300,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 185,000 | 1,393,510 (5%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 98,375 | 1,208,510 (4%) | 0% | 3.6 | 350,215 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 45,909 | 1,306,885 (4%) | 0% | 3.6 | 163,436 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 32,039 | 1,352,794 (4%) | 0% | 3.6 | 115,661 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth Hecht P. | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 750,000 | 1,554,968 (5%) | 2% | 0 | Common Stock | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 15,853 | 18,839 (0%) | 0% | 0 | Ordinary Shares | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 15,853 | 0 | - | - | Restricted Share Units | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 350,000 | 797,758 (2%) | 1% | 0 | Common Stock | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2022 | 36,798 | 0 | - | - | Restricted Share Units | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2022 | 36,798 | 44,805 (0%) | 0% | 0 | Ordinary Shares | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 237,795 | 237,795 | - | - | Restricted Share Units | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2022 | 7,642 | 8,007 (0%) | 0% | 0 | Ordinary Shares | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2022 | 7,642 | 0 | - | - | Restricted Share Units | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.46 per share. | 29 Jan 2022 | 45,909 | 1,380,802 (5%) | 0% | 2.5 | 112,936 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 29 Jan 2022 | 33,488 | 1,506,835 (5%) | 0% | 1.1 | 37,507 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.24 per share. | 29 Jan 2022 | 33,488 | 1,446,386 (5%) | 0% | 2.2 | 75,013 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 29 Jan 2022 | 21,177 | 1,485,658 (5%) | 0% | 1.3 | 26,683 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 29 Jan 2022 | 19,675 | 1,426,711 (5%) | 0% | 2.7 | 52,336 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.11 per share. | 29 Jan 2022 | 14,037 | 1,544,771 (5%) | 0% | 2.1 | 29,618 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 29 Jan 2022 | 5,784 | 1,479,874 (5%) | 0% | 1.2 | 7,172 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.11 per share. | 29 Jan 2022 | 4,448 | 1,540,323 (5%) | 0% | 2.1 | 9,385 | Common Stock |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 225,000 | 436,821 (1%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 180,000 | 0 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 180,000 | 206,366 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 150,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 65,295 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 65,295 | 65,295 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 32,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 30,879 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 30,879 | 30,879 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 26,366 | 26,366 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 26,366 | 180,000 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 3,826 | 3,826 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 3,826 | 0 | - | - | Stock Option (Right to Buy) | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 36,798 | 36,798 | - | - | Restricted Stock Units | |
| Iterum Therapeutics Plc | Beth P. Hecht | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 7,642 | 7,642 | - | - | Restricted Stock Units | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 150,000 | 210,814 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges